Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab dose-finding study in chronic spontaneous urticaria
2014-005559-16Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ligelizumab in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Novartis. Primary endpoint: Complete hives response at Week 12. Started Apr 2015; status: completed.
02
Drugs
ligelizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2014-005559-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005559-16.